Cat. No. ARG0134
The Tnfaip8 Knockout B16 Cell Line is a CRISPR/Cas9-edited mouse melanoma model with disruption of Tnfaip8 in the B16 host background. B16 cells are widely used to study aggressive melanoma growth, invasion, metastasis, and tumor-immune interactions. TNFAIP8 is a TNF-alpha- and NF-kappaB-responsive TIPE family protein that supports cell survival, modulates CASP8/CASP3-linked apoptosis regulation, and contributes to PI3K-AKT- and RAC1-associated migration programs through phosphoinositide-dependent mechanisms. This knockout model is useful for apoptosis assays, phospho-AKT analysis, migration and invasion studies, RNA-seq, and drug response or sensitization studies in melanoma.
| Host Cell | B16 |
| Morphology | Fibroblast-like |
| Age | Unknown |
| Gene Name | Tnfaip8 |
| Gene Identifier | NCBI Gene ID 106869 |
| Temperature | 37°C |
| Atmosphere | 5% CO₂ |
| Sterility testing | Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination. |
| Mycoplasma testing | Negative for mycoplasma through PCR analysis |
| Pathogens | Cells tested negative for HIV-1, HBV, and HCV. |
Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.
This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.
The Tnfaip8 Knockout B16 Cell Line is a CRISPR/Cas9-engineered mouse melanoma cell model in which the Tnfaip8 gene has been disrupted to abolish functional gene expression. This stable knockout line is generated in the B16 host background, a tumor-derived melanocytic cell line, and provides an in vitro system for investigating TNFAIP8-dependent mechanisms in melanoma biology. The model is suited for studies requiring defined genetic loss of an inflammation-responsive survival factor within a well-established syngeneic murine tumor context.
B16 cells are widely used as an aggressive mouse melanoma model because they recapitulate key features of melanoma growth, pigmentation, invasive behavior, metastatic potential, and responsiveness to immune and pharmacologic perturbation. As a transplantable and experimentally tractable melanoma system, B16 supports investigation of tumor cell-intrinsic survival programs as well as processes linked to tumor-host interaction. This background is therefore highly relevant for studying pathways that integrate inflammatory stimuli with tumor progression, motility, and resistance to cell death.
TNFAIP8 is a TNF-alpha-inducible member of the TIPE family that functions downstream of inflammatory signaling to promote cell survival and tumor progression. It is regulated by TNF-alpha, NF-kappaB, inflammatory cytokines, TLR signaling, and cellular stress stimuli, and is mechanistically linked to TNFR1-proximal signaling, the IKK complex, and the RELA/p65 and NFKB1/p50 transcriptional machinery. TNFAIP8 has been associated with suppression of apoptosis through effects on caspase-regulatory pathways, including CASP8 and CASP3 activation status, and with BCL2 family-dependent survival outputs involving BCL2 and BAX. In parallel, TNFAIP8 interacts with phosphoinositides such as PIP2 and PIP3 and has been implicated in PI3K-AKT and RAC1-dependent migratory signaling, connecting inflammatory inputs to cell motility, chemotaxis, and invasion.
Loss of Tnfaip8 in B16 cells provides a relevant platform for defining how melanoma cells depend on TNFAIP8 to couple NF-kappaB-associated inflammatory signaling with anti-apoptotic and pro-migratory phenotypes. In this host-cell context, the knockout can be used to assess altered apoptosis sensitivity, changes in AKT signaling outputs, shifts in RAC1-associated movement, and broader effects on tumor-immune regulatory programs. Because B16 is frequently used to model melanoma progression and therapeutic response, this system is also useful for evaluating pathway dependency under inflammatory or stress-inducing conditions.
Applications include western blotting and RT-qPCR to profile TNF-alpha/NF-kappaB pathway responses; RNA-seq for gene-expression changes linked to survival, inflammation, or invasion; annexin V/propidium iodide flow cytometry, caspase activity assays, and apoptosis assays to quantify cell death susceptibility; and phospho-AKT analysis to examine PI3K-AKT pathway consequences of Tnfaip8 loss. Investigators may also apply immunofluorescence, migration assays, invasion assays, colony formation assays, co-immunoprecipitation, and drug sensitivity studies to dissect melanoma survival mechanisms, metastasis-related phenotypes, and response sensitization in a defined knockout background. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.
